Check-Cap (NASDAQ:CHEK) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a report issued on Friday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Price Performance

Shares of NASDAQ CHEK opened at $0.67 on Friday. The stock has a market capitalization of $3.90 million, a P/E ratio of -0.22 and a beta of 0.20. Check-Cap has a one year low of $0.56 and a one year high of $3.04. The firm’s 50 day simple moving average is $0.79 and its two-hundred day simple moving average is $1.00.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.